Novus Medical Clinica S.R.L.
- Address
- Block 32 E And F Ground Floor, Strada Vasile Lupu 2, 100018 Ploieşti, Romania
Novus Medical Clinica S.R.L. - Diabetes and Metabolic Research
Novus Medical Clinica S.R.L. is a clinical research center specializing in metabolic disorders and endocrinology research. The center focuses on advancing treatment strategies for patients with diabetes and related metabolic conditions, with particular emphasis on optimizing therapeutic regimens to improve patient outcomes and quality of life.
- Type 2 diabetes management and insulin optimization studies
- Novel GLP-1 receptor agonist therapies including semaglutide
- Combination therapy approaches for patients with overweight and metabolic disorders
The center conducts sophisticated clinical trials evaluating innovative treatment strategies, including comparative studies of semaglutide combined with dose-reduced basal insulin versus conventional insulin titration approaches. Their research aims to identify more effective and patient-friendly treatment regimens that address both glycemic control and weight management in individuals with type 2 diabetes and overweight, contributing to the development of evidence-based therapeutic optimization strategies in metabolic medicine.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novo Nordisk A/S2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Novus Medical Clinica S.R.L.
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Dose-Response Study of NNC0487-0111 in Type 2 Diabetes Patients Inadequately Controlled with Metformin and/or SGLT2 Inhibitors | Novo Nordisk A/S | Phase II | Not Recruiting | Jul 2024 | Oct 2025 |
IMP list
lock Showing 1 of 4 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dapagliflozin Propanediol | 1 | Unknown | 2024-07-26 | 2024-07-26 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.